Compare WHR & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | XENE |
|---|---|---|
| Founded | 1911 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.2B |
| IPO Year | 1994 | 2014 |
| Metric | WHR | XENE |
|---|---|---|
| Price | $51.92 | $54.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $82.00 | $67.17 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.71% | N/A |
| EPS Growth | ★ 196.42 | N/A |
| EPS | ★ 5.66 | N/A |
| Revenue | ★ $21,253,000,000.00 | $311,000.00 |
| Revenue This Year | $0.01 | N/A |
| Revenue Next Year | $3.46 | $2,436.26 |
| P/E Ratio | $9.49 | ★ N/A |
| Revenue Growth | ★ 2.58 | N/A |
| 52 Week Low | $52.01 | $26.74 |
| 52 Week High | $111.96 | $62.91 |
| Indicator | WHR | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 27.21 | 58.97 |
| Support Level | N/A | $39.93 |
| Resistance Level | $80.65 | $62.91 |
| Average True Range (ATR) | 2.06 | 2.05 |
| MACD | 0.43 | -0.33 |
| Stochastic Oscillator | 1.69 | 20.46 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.